A:concurrent chemoradiotherapy

2 trials

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Affiliated hospital of Jiangnan University

Conditions

Esophageal Squamous Carcinomaesophageal squamous cell carcinoma

Phase 2

A multicenter, randomized, controlled, phase II trial for comparing radical concurrent chemoradiotherapy with/without Toripalimab (JS001) and consolidated immunotherapy in locally advanced esophageal squamous cell carcinoma

Active, not recruitingChiCTR2000032369

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Collegeesophageal squamous cell carcinoma

Start: 2020-06-01Updated: 2020-04-27

Unknown Phase

Clinical treatment strategy study of postoperative local recurrence in anastomotic stoma and its adjacent areas of esophageal squamous cell carcinoma : the efficacy of nimotuzumab combined with concurrent chemoradiotherapy guided by EGFR expression

Active, not recruitingChiCTR2200063875

Affiliated hospital of Jiangnan UniversityEsophageal Squamous Carcinoma

Start: 2022-09-06Updated: 2023-04-17

Related Papers

Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal squamous cell carcinoma: A phase II study.

Journal of Clinical Oncology2026-05-27